Proactive Monitoring of Remicade Levels in IBD Patients May Decrease Risk of Hospitalization, Study Finds

Proactive Monitoring of Remicade Levels in IBD Patients May Decrease Risk of Hospitalization, Study Finds
Proactive monitoring of the levels of Remicade (infliximab) in patients with inflammatory bowel disease (IBD) may help promote patients’ health and decrease their hospital visits, according to scientists from the Center for Inflammatory Bowel Disease at the Beth Israel Deaconess Medical Center (BIDMC) and the University of Pennsylvania. The study, “Proactive Compared to Reactive Therapeutic Drug Monitoring

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. I wonder if the “control” group showed up for regular “sham” blood tests (just not TDM) on the same schedule as the “proactive” group. There are, after all, some benefits to regular office visits, which by the way are a good marker of patients’ motivation and adherence!

Leave a Comment

Your email address will not be published. Required fields are marked *